Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.6.3897

Prognostic Value of T Cell Immunoglobulin Mucin-3 in Prostate Cancer  

Piao, Yong-Rui (Department of Urology, Affiliated Hospital of YanBian University)
Piao, Long-Zhen (Department of Oncology, Affiliated Hospital of YanBian University)
Zhu, Lian-Hua (Department of Dermatology and Venereology, Affiliated Hospital of YanBian University)
Jin, Zhe-Hu (Department of Dermatology and Venereology, Affiliated Hospital of YanBian University)
Dong, Xiu-Zhe (Department of Urology, Affiliated Hospital of YanBian University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.6, 2013 , pp. 3897-3901 More about this Journal
Abstract
Background: Optimal treatment for prostate cancer remains a challenge worldwide. Recently, T cell immunoglobulin mucin-3 (TIM-3) has been implicated in tumor biology but its contribution prostate cancer remains unclear. The aim of this study was to investigate the role of TIM-3 as a prognostic marker in patients with prostate cancer. Methods: TIM-3 protein expression was determined by immunohistochemistry and Western blotting in 137 prostate cancer tumor samples and paired adjacent benign tissue. We also performed cell proliferation assays using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl- 2H tetrazolium bromide (MTT) and cell invasion assays. The effects of small interfering RNA (siRNA)-mediated knockdown of TIM-3 (TIM-3 siRNA) in two human prostate cancer cell lines were also evaluated. Results: TIM-3 expression was higher in prostate cancer tissue than in the adjacent benign tissue (P<0.001). High TIM-3 expression was an independent predictor of both recurrence-free survival and progression-free survival. TIM-3 protein was expressed in both prostate cancer cell lines and knockdown suppressed their proliferation and invasion capacity. Conclusions: TIM-3 expression is associated with a poor prognosis in prostate cancer. Taken together, our resutlts indicate that TIM-3 is a potential prognostic marker in prostate cancer.
Keywords
TIM-3; prostate cancer; prognosis; biomarker;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Abildgaard MO, Borre M, Mortensen MM, et al (2012). Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis. Int J Cancer, 130, 885-95.   DOI   ScienceOn
2 Cai C, Wang L, Wu Z, et al (2012). T-cell immunoglobulin- and mucin-domain- containing molecule 3 gene polymorphisms and renal cell carcinoma. DNA Cell Biol, 31, 1285-9.   DOI   ScienceOn
3 Facompre N, El-Bayoumy K (2009).Potential stages for prostate cancer prevention with selenium: implications for cancer survivors. Cancer Res, 69, 2699-703.   DOI   ScienceOn
4 Fourcade J, Sun Z, Benallaoua M, et al (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigenspecific CD8+T cell dysfunction in melanoma patients. J Exp Med, 207, 2175-86.   DOI   ScienceOn
5 Geng H, Zhang GM, Li D, et al (2006). Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol, 176, 1411-20.   DOI
6 Huang X, Bai X, Cao Y, et al (2010). Lymphoma endothelium preferentially expresses TIM-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med, 207, 505-20.   DOI   ScienceOn
7 Jan M, Chao MP, Cha AC, et al (2011). Prospective separation of normal and leukemic stem cells based on differential expression of Tim-3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci, 108, 5009-14.   DOI   ScienceOn
8 Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.   DOI
9 Kikushige Y, Shima T, Takayanagi S, et al (2010). Tim-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell, 7, 708-17.   DOI   ScienceOn
10 Sakuishi K, Apetoh L, Sullivan JM, et al (2010). Targeting TIM-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med, 207, 2187-94.   DOI   ScienceOn
11 Sugiyama Y, Masumori N, Fukuta F, et al (2013). Influence of isoflavone intake and equol-producing intestinal flora on prostate cancer risk. Asian Pac J Cancer Prev, 14, 1-4.   과학기술학회마을   DOI   ScienceOn
12 Wiener Z, Kohalmi B, Pocza P, et al (2007). TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol, 127, 906-14.   DOI   ScienceOn
13 Xu LW, Qian M, Jia RP, et al (2012). Expression and significance of microsomal prostaglandin synthase-1 (mPGES-1) and Beclin-1 in the development of prostate cancer. Asian Pac J Cancer Prev, 13, 1639-44.   과학기술학회마을   DOI   ScienceOn
14 Yang X, Liang L, Zhang XF, et al (2013). MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting IL-6-Stat3 pathway. Hepatology, 58, 158-70.   DOI   ScienceOn
15 Zhuang X, Zhang X, Xia X, et al (2012). Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol, 137, 978 - 85.   DOI   ScienceOn
16 Yun UJ, Park SE, Jo YS, Kim J, Shin DY (2012). DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors. Cancer Lett, 323, 155-60.   DOI   ScienceOn